Clinical Trial Results:
A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1)
Summary
|
|
EudraCT number |
2004-001593-10 |
Trial protocol |
IT GB |
Global completion date |
01 Feb 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Nov 2016
|
First version publication date |
13 Nov 2016
|
Other versions |
|
Summary report(s) |
2004-001593-10_EudraCT DIsclosure Synopsis.pdf |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.